Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27256299 | 0.80 | CA1 (0.36) | — | |
| SCHEMBL28022866 | 0.77 | KDM5A (0.41) | MAPTMEN1KMT2A | |
| SCHEMBL28041871 | 0.77 | KDM5A (0.41) | MAPTMEN1KMT2A | |
| SCHEMBL27510562 | 0.77 | KDM5A (0.41) | MAPTMEN1KMT2A | |
| SCHEMBL27256255 | 0.77 | ALDH1A1 (0.37) | DGAT1KMT2A | |
| SCHEMBL19530758 | 0.77 | ALDH1A1 (0.37) | DGAT1MAPTMEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL27716792 | 0.76 | ALDH1A1 (0.36) | KMT2A | |
| SCHEMBL27281395 | 0.76 | MAPT (0.38) | MAPTMEN1KMT2A | |
| SCHEMBL25657471 | 0.73 | DGAT1 (0.33) | DGAT1 | |
| Acetic Acid SCHEMBL27610013 | 0.73 | ALDH1A1 (0.34) | MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | DGAT1 3383/4885MAPT 4527/4885MEN1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.